Clinical Practice Guideline for the Staging and Management of Cardiovascular-Kidney-Metabolic Syndrome

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Circulation https://doi.org/10.1161/CIR.0000000000001453
Dr. Chiadi E. Ndumele et al.

Points

The American Heart Association and American College of Cardiology introduced a comprehensive clinical guideline to manage the interconnected complications of cardiovascular-kidney-metabolic syndrome.
Epidemiological data indicate that nearly 90 percent of adults in the United States present with at least one major risk factor including obesity or reduced kidney function.
The guideline establishes a structured four-stage classification system that spans from early metabolic risk components to subclinical disease and advanced multiorgan failure.
Clinicians are advised to utilize the new PREVENT equations to estimate comprehensive 10-year and 30-year cardiovascular risk by directly integrating renal and metabolic patient markers.
Therapeutic recommendations introduce GLP-1 receptor agonists alongside metabolic surgery and lifestyle modifications to aggressively reduce the incidence of major adverse cardiac events.

Summary

This clinical guideline evaluated the framework for preventing, detecting, evaluating, and managing cardiovascular-kidney-metabolic (CKM) syndrome, an interconnected systemic disorder. Nearly 90% of United States adults present with at least one predisposing CKM risk factor, such as excess body weight, hypertension, dyslipidemia, hyperglycemia, or reduced glomerular filtration. Furthermore, recent epidemiological statistics show that 40% of adults and 21% of children and adolescents in the United States have obesity. Given that metabolic dysfunction, renal decline, and atherosclerotic progression do not occur in isolation, this multi-organizational report sought to formalize early screening paradigms to lower multiorgan complications before a major adverse cardiac event manifests.

The consensus document establishes a comprehensive four-stage classification matrix to risk-stratify patients and tailor individual prophylactic interventions. Stage 1 comprises individuals with overweight, obesity, or prediabetes without additional metabolic or structural cardiovascular disease. Stage 2 includes individuals presenting with overt chronic kidney disease or metabolic factors like type 2 diabetes. Stage 3 defines individuals with subclinical, asymptomatic cardiovascular disease or a high predicted 10-year risk calculated using the novel Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations, which integrate renal and metabolic parameters to generate precise 10- and 30-year risk estimates. Stage 4 comprises patients with clinically diagnosed, overt cardiovascular disease coexisting with existing metabolic or renal risk profiles.

To optimize long-term clinical outcomes, the guideline mandates a comprehensive interdisciplinary approach combining strict lifestyle modification via the Life’s Essential 8 metrics with targeted pharmacological and surgical therapies. For the first time, glucagon-like peptide-1 (GLP-1)-based therapies are recommended for select high-risk patients with obesity or type 2 diabetes to systematically reduce macrovascular risks. In severe refractory cases, metabolic and bariatric surgery are endorsed as viable therapeutic options. Additionally, clinicians are encouraged to systematically screen for adverse social determinants of health, such as food insecurity and financial strain. While prospective long-term clinical trials remain necessary to establish lifetime hazard ratios under this unified care paradigm, these recommendations establish an integrated clinical protocol to defend multi-organ health.

Link to the article: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001453

References

Writing Committee Members, Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., De Boer, I. H., Ellison, D. H., Evangelista, L. S., Heffron, S. P., Kazi, D. S., Kulshreshtha, A., Lingvay, I., Low Wang, C. C., … Weiner, D. E. (2026). 2026 aha/acc/ada/asn guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: A report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation, CIR.0000000000001453. https://doi.org/10.1161/CIR.0000000000001453